Cas No.: | 1308631-40-4 |
Chemical Name: | N-(4-chloro-2-fluorophenyl)-2-hydroxybenzamide |
Synonyms: | NDMC-101;NDMC 101 |
SMILES: | C(NC1=CC=C(Cl)C=C1F)(=O)C1=CC=CC=C1O |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | A small molecule that inhibits NFATc1 and NF-κB activity, inhibits RANKL-induced osteoclastogenesis in vivo; markedly inhibits RANKL-induced formation of TRAP+ multinucleated cells in RAW264.7 and bone marrow macrophage cells (BMMs); significantly reduces the bone-resorbing activity of mature osteoclasts; reduces arthritic index and mitigated bone erosion in CIA mice. |
In Vitro: | NDMC101 (10-15 µM) inhibits RANKL-induced osteoclast differentiation of bone marrow-derived macrophages (BMDMs) and RAW 264.7 cells[1]. NDMC101 (15 µM) decreases RANKL-induced expression of the osteoclastogenic genes Nfatc1, Acp5, Ctsk, Oscar, Itgb3, and Dcstamp in BMDMs[1]. |
References: | [1]. Chia-Pi Cheng, et al. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77. [2]. Jun-Ting Liou, et al. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32. |